Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence

Conclusion:
There is no compelling evidence that any clinically available insulin analogue (Aspart, Determir, Glargine, Glulisine or Lispro), nor human insulin increases breast cancer risk. Overall, the data suggests that insulin treatment is not involved in breast tumour initiation, but might induce breast tumour progression by up regulating mitogenic signalling pathways.

Source: Breast Cancer Research - August 5, 2015 Category: Cancer & Oncology Authors: Heleen BronsveldBas ter BraakØystein KarlstadPeter VestergaardJakob Starup-LindeMarloes BazelierMarie De BruinAnthonius de BoerChristine SiezenBob van de WaterJan van der LaanMarjanka Schmidt Source Type: research